Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;198(1):83-85.
doi: 10.1007/s00066-021-01880-4. Epub 2021 Dec 6.

[Definitive chemoradiotherapy of locally advanced head and neck cancer in combination with immune checkpoint inhibition-new concepts required]

[Article in German]
Markus Hecht  1 , Rainer Fietkau  2 , Udo S Gaipl  2
Affiliations
Comment

[Definitive chemoradiotherapy of locally advanced head and neck cancer in combination with immune checkpoint inhibition-new concepts required]

[Article in German]
Markus Hecht et al. Strahlenther Onkol. 2022 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–1928. doi: 10.1016/S0140-6736(19)32591-7. - DOI - PubMed
    1. Ruckert M, Flohr AS, Hecht M, Gaipl US. Radiotherapy and the immune system: More than just immune suppression. Stem Cells. 2021;39:1155–1165. doi: 10.1002/stem.3391. - DOI - PubMed
    1. Fietkau R, Hecht M, Hofner B, et al. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: the pacCis-trial. Radiother Oncol. 2020;144:209–217. doi: 10.1016/j.radonc.2020.01.016. - DOI - PubMed
    1. Zhou JG, Donaubauer AJ, Frey B, et al. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. J Immunother Cancer. 2021;9(2):e001845. doi: 10.1136/jitc-2020-001845. - DOI - PMC - PubMed
    1. Hecht M, Eckstein M, Rutzner S, et al. Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration. J Clin Oncol. 2021;39(suppl 15):abstr 6007. doi: 10.1200/JCO.2021.39.15_suppl.6007. - DOI

Substances